Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly TPC in Palliative SCCHN
NCT01437449Phase 2Completed
- Sponsor
- Stanford University
- Start
- Oct 2011
- Primary completion
- Sep 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, Cisplatin micelle injection (HA132) and KL-140 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Stanford University. Primary endpoint: Overall Response Rate at 8 weeks. Started Oct 2011; status: completed.
02
Drugs
docetaxelCisplatin micelle injection (HA132)KL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01437449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01437449.